Nivolumab 40 mg in 4 ml Injection

DRUG3 trials

Sponsors

St. Petersburg State Pavlov Medical University, Hospital Israelita Albert Einstein, National Research Center for Hematology, Russia

Conditions

Hodgkin LymphomaPrimary Mediastinal LymphomaUterine Cervical Neoplasms

Phase 1

Treatment With Nivolumab at the Fixed Dose 40 mg (Nivo40) in Patients With Relapsed/Refractory Hodgkins Lymphoma

CompletedNCT03343665

St. Petersburg State Pavlov Medical UniversityHodgkin Lymphoma

Start: 2017-08-01End: 2019-12-20Updated: 2020-01-23

Phase 2

Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer

RecruitingNCT05492123

Hospital Israelita Albert EinsteinUterine Cervical Neoplasms

Start: 2022-08-30End: 2028-03-31Target: 112Updated: 2024-01-05

Phase 3

Multicenter Study of Safety and Efficacy Nivolumab at the Fixed Dose 40 mg (Nivo40) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed PMBL

RecruitingNCT06188676

National Research Center for Hematology, RussiaPrimary Mediastinal Lymphoma

Start: 2022-04-01End: 2029-04-01Target: 100Updated: 2024-01-03

Related Papers

Five-Year Follow-Up of Patients With Relapsed and Refractory Classic Hodgkin Lymphoma Treated With Low-Dose Nivolumab (40 mg): A Matched Cohort Study With Standard-Dose Therapy.

2025-11-01

Randomized phase II study to evaluate treatment with induction therapy with nivolumab plus ipilimumab, followed by nivolumab with chemoradiotherapy versus standard of care with chemoradiotherapy for women with locally advanced cervical cancer.

Journal of Clinical Oncology2025-05-28

P062: The efficacy and safety of nivolumab 40 mg therapy versus 3 mg/kg in patients with relapsed and refractory classic Hodgkin lymphoma

HemaSphere2022-10-012 citations

P1080: COMPARISON OF NIVOLUMAB 40 MG EFFICACY VERSUS 3 MG/KG IN PATIENTS WITH RELAPSED AND REFRACTORY CLASSIC HODGKIN LYMPHOMA

HemaSphere2022-06-012 citations

A Phase 2 Study of Nivolumab Using a Fixed Dose of 40 mg (Nivo40) in Patients With Relapsed/Refractory Hodgkin Lymphoma.

2020-09-2326 citations